Detalles de la búsqueda
1.
Anti-infliximab antibodies and low infliximab levels correlate with drug discontinuation in pediatric inflammatory bowel disease.
J Pediatr Gastroenterol Nutr
; 78(2): 261-271, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38374555
2.
Sexual Health in Sexual and Gender Minority Patients with Inflammatory Bowel Disease.
Dig Dis Sci
; 69(3): 743-748, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38267727
3.
Combination Therapy With Immunomodulators Improves the Pharmacokinetics of Infliximab But Not Vedolizumab or Ustekinumab.
Clin Gastroenterol Hepatol
; 21(11): 2908-2917.e10, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36280102
4.
Higher Postinduction Infliximab Concentrations Are Associated With Favorable Clinical Outcomes in Pediatric Crohn's Disease: A Post Hoc Analysis of the REACH Trial.
Am J Gastroenterol
; 118(3): 485-490, 2023 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36624036
5.
Patients With Inflammatory Bowel Diseases and Higher Visceral Adipose Tissue Burden May Benefit From Higher Infliximab Concentrations to Achieve Remission.
Am J Gastroenterol
; 118(11): 2005-2013, 2023 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37207314
6.
Patients With Low Drug Levels or Antibodies to a Prior Anti-Tumor Necrosis Factor Are More Likely to Develop Antibodies to a Subsequent Anti-Tumor Necrosis Factor.
Clin Gastroenterol Hepatol
; 20(2): 465-467.e2, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33421628
7.
Assessing the repercussions of COVID-19 pandemic on symptoms, disease management, and emotional well-being in patients with inflammatory bowel disease: a multi-site survey study.
Scand J Gastroenterol
; 57(4): 406-414, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34894999
8.
Lymphoma in Pediatric-Onset Inflammatory Bowel Disease Treated with Infliximab Monotherapy: A Case Series.
Dig Dis Sci
; 67(1): 252-258, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33595782
9.
Appropriateness of Medical and Surgical Treatments for Chronic Pouchitis Using RAND/UCLA Appropriateness Methodology.
Dig Dis Sci
; 67(10): 4687-4694, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35006492
10.
Comparison of Assays for Therapeutic Monitoring of Infliximab and Adalimumab in Patients With Inflammatory Bowel Diseases.
Clin Gastroenterol Hepatol
; 19(4): 839-841.e2, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32147594
11.
Higher Postinduction Infliximab Concentrations Are Associated With Improved Clinical Outcomes in Fistulizing Crohn's Disease: An ACCENT-II Post Hoc Analysis.
Am J Gastroenterol
; 116(5): 1007-1014, 2021 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33929379
12.
A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease.
Am J Gastroenterol
; 116(10): 2014-2025, 2021 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34388143
13.
Therapeutic drug monitoring in patients on biologics: lessons from gastroenterology.
Curr Opin Rheumatol
; 32(4): 371-379, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32412995
14.
Biological therapies in inflammatory bowel disease: Beyond anti-TNF therapies.
Clin Immunol
; 206: 9-14, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-29545207
15.
Proactive Therapeutic Drug Monitoring of Adalimumab in Patients With Crohn's Disease.
Gastroenterology
; 164(1): 164-165, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35436497
16.
Risankizumab concentration but not IL-22 levels are associated with clinical and biochemical remission in patients with Crohn's disease.
Clin Gastroenterol Hepatol
; 2024 May 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38705437
17.
Higher adalimumab concentration is associated with complete fistula healing in patients with perianal fistulizing Crohn's disease.
Clin Gastroenterol Hepatol
; 2024 Apr 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-38692557
18.
Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis.
Clin Gastroenterol Hepatol
; 17(1): 139-147, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30012431
19.
Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases.
Clin Gastroenterol Hepatol
; 17(9): 1655-1668.e3, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-30928454
20.
Therapeutic drug monitoring in inflammatory bowel disease: for every patient and every drug?
Curr Opin Gastroenterol
; 35(4): 302-310, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30973355